| Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I KN Moore, AM Oza, N Colombo, A Oaknin, G Scambia, D Lorusso, ... Annals of Oncology 32 (6), 757-765, 2021 | 187 | 2021 |
| Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study UA Matulonis, D Lorusso, A Oaknin, S Pignata, A Dean, H Denys, ... Journal of clinical oncology 41 (13), 2436-2445, 2023 | 179 | 2023 |
| Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study A Morikawa, DM Peereboom, HR Thorsheim, R Samala, R Balyan, ... Neuro-oncology 17 (2), 289-295, 2015 | 172 | 2015 |
| The role of CDK4/6 inhibition in breast cancer CG Murphy, MN Dickler The oncologist 20 (5), 483-490, 2015 | 156 | 2015 |
| Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies CG Murphy, MN Dickler Endocrine-related cancer 23 (8), R337-R352, 2016 | 137 | 2016 |
| Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer CG Murphy, D Mallam, S Stein, S Patil, J Howard, N Sklarin, CA Hudis, ... Cancer 118 (13), 3254-3259, 2012 | 134 | 2012 |
| Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ... The lancet oncology 19 (1), 127-138, 2018 | 117 | 2018 |
| HER2 breast cancer therapies: a review CG Murphy, S Modi Biologics: Targets and Therapy, 289-301, 2009 | 114 | 2009 |
| BRCA gene structure and function in tumor suppression: a repair-centric perspective CG Murphy, ME Moynahan The Cancer Journal 16 (1), 39-47, 2010 | 93 | 2010 |
| Recent advances in novel targeted therapies for HER2-positive breast cancer CG Murphy, PG Morris Anti-cancer drugs 23 (8), 765-776, 2012 | 89 | 2012 |
| CDK4/6 inhibitors in breast cancer T Dukelow, D Kishan, M Khasraw, CG Murphy Anti-cancer drugs 26 (8), 797-806, 2015 | 62 | 2015 |
| HER2-positive breast cancer: beyond trastuzumab CG Murphy, M Fornier Oncology 24 (5), 410, 2010 | 62 | 2010 |
| Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays E Brogi, CG Murphy, ML Johnson, AK Conlin, M Hsu, S Patil, M Akram, ... Annals of oncology 22 (12), 2597-2603, 2011 | 59 | 2011 |
| PARP inhibitors in clinical use induce genomic instability in normal human cells S Ito, CG Murphy, E Doubrovina, M Jasin, ME Moynahan PLoS One 11 (7), e0159341, 2016 | 53 | 2016 |
| The role of CDK4/6 inhibitors in breast cancer CG Murphy Current treatment options in oncology 20 (6), 52, 2019 | 52 | 2019 |
| Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: a single-institution experience C Murphy, S Byrne, G Ahmed, A Kenny, J Gallagher, H Harvey, ... Dose-Response 16 (4), 1559325818803042, 2018 | 52 | 2018 |
| Cancer‐related fatigue and self‐care agency: A multicentre survey of patients receiving chemotherapy P O'Regan, G McCarthy, S O'Reilly, D Power, BH Bird, CG Murphy, ... Journal of clinical nursing 28 (23-24), 4424-4433, 2019 | 51 | 2019 |
| FORWARD I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients … K Moore, A Oza, N Colombo, A Oaknin, G Scambia, D Lorusso, ... Annals of Oncology 30, v403, 2019 | 48 | 2019 |
| Limited overall survival in patients with brain metastases from triple negative breast cancer PG Morris, CG Murphy, D Mallam, M Accordino, S Patil, J Howard, ... The breast journal 18 (4), 345-350, 2012 | 45 | 2012 |
| Cystoid Macular Edema Secondary tonab-Paclitaxel Therapy CG Murphy, JB Walsh, CA Hudis, D Lake, M Theodoulou Journal of Clinical Oncology 28 (33), e684-e687, 2010 | 41 | 2010 |
